Iranian Red Crescent Medical Journal

Published by: Kowsar

Comparison of Anticancer Effects of Carbamazepine and Valproic Acid

Ladan Akbarzadeh 1 , * , Taraneh Moini Zanjani 1 and Masoumeh Sabetkasaei 1
Authors Information
1 Department of Pharmacology, Shahid Beheshti University, Tehran, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: October 01, 2016, 18 (10); e37230
  • Published Online: August 4, 2016
  • Article Type: Research Article
  • Received: February 19, 2016
  • Revised: May 22, 2016
  • Accepted: June 14, 2016
  • DOI: 10.5812/ircmj.37230

To Cite: Akbarzadeh L, Moini Zanjani T, Sabetkasaei M. Comparison of Anticancer Effects of Carbamazepine and Valproic Acid, Iran Red Crescent Med J. 2016 ; 18(10):e37230. doi: 10.5812/ircmj.37230.

Abstract
Copyright © 2016, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. McNamara JO. Drugs effective in the therapy of the epilepsies. 2011; : 583-607
  • 2. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol. 2001; 13(6): 477-83[PubMed]
  • 3. Kramer OH, Gottlicher M, Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol Metab. 2001; 12(7): 294-300[PubMed]
  • 4. Sandor V. Phase I trial of the histone deacetylase inhibitor, depsipeptide in refractory neoplasms. Cancer Res. 2002; 8(3): 718-28
  • 5. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001; 1(3): 194-202[DOI][PubMed]
  • 6. Blaheta RA, Michaelis M, Driever PH, Cinatl J. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev. 2005; 25(4): 383-97[DOI][PubMed]
  • 7. Beutler AS, Li S, Nicol R, Walsh MJ. Carbamazepine is an inhibitor of histone deacetylases. Life Sci. 2005; 76(26): 3107-15[DOI][PubMed]
  • 8. Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem. 2013; 46(15): 1323-38[DOI][PubMed]
  • 9. Xu R, Zhou B, Fung PC, Li X. Recent advances in the treatment of colon cancer. Histol Histopathol. 2006; 21(8): 867-72[PubMed]
  • 10. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2): 69-90[DOI][PubMed]
  • 11. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3): 469-80[DOI][PubMed]
  • 12. Khalil S, Tan GA, Giri DD, Zhou XK, Howe LR. Activation status of Wnt/ss-catenin signaling in normal and neoplastic breast tissues: relationship to HER2/neu expression in human and mouse. PLoS One. 2012; 7(3): 33421[DOI][PubMed]
  • 13. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007; 26(37): 5420-32[DOI][PubMed]
  • 14. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007; 26(37): 5541-52[DOI][PubMed]
  • 15. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res. 2004; 10(3): 1141-9[PubMed]
  • 16. Glaser KB. Gene expression histone deacetylase inhibitors in T24 and MDA cell lines. Cancer Ther. 2003; 2(2): 151-63
  • 17. Gray SG, Qian CN, Furge K, Guo X, Teh BT. Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int J Oncol. 2004; 24(4): 773-95[PubMed]
  • 18. de Ruijter AJ, Meinsma RJ, Bosma P, Kemp S, Caron HN, van Kuilenburg AB. Gene expression profiling in response to the histone deacetylase inhibitor BL1521 in neuroblastoma. Exp Cell Res. 2005; 309(2): 451-67[DOI][PubMed]
  • 19. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001; 276(39): 36734-41[DOI][PubMed]
  • 20. Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 2002; 16(10): 669-94[PubMed]
  • 21. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001; 20(24): 6969-78[DOI][PubMed]
  • 22. Blaheta RA, Cinatl J. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev. 2002; 22(5): 492-511[DOI][PubMed]
  • 23. Stettner M, Kramer G, Strauss A, Kvitkina T, Ohle S, Kieseier BC, et al. Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer. Eur J Cancer Prev. 2012; 21(1): 55-64[DOI][PubMed]
  • 24. Hoti N, Chowdhury W, Hsieh JT, Sachs MD, Lupold SE, Rodriguez R. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Mol Ther. 2006; 14(6): 768-78[DOI][PubMed]
  • 25. Kutko MC. Histone deacetylase 8 inhibitors induce growth suppression in human rhabdomyosarcoma in vitro. Cancer Res. 2003; 9(15): 5749-55
  • 26. Sawa H, Murakami H, Ohshima Y, Sugino T, Nakajyo T, Kisanuki T, et al. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor Pathol. 2001; 18(2): 109-14[PubMed]
  • 27. Li GC, Zhang X, Pan TJ, Chen Z, Ye ZQ. Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest. Int J Urol. 2006; 13(5): 581-6[DOI][PubMed]
  • 28. Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus. Science. 2000; 287(5458): 1606-9[PubMed]
  • 29. Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene. 2002; 21(3): 427-36[DOI][PubMed]
  • 30. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med. 2001; 7(4): 437-43[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments